MigraineMind research summary
Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study.
Headache | 2026
Clinical trialSummary
This study examined weight loss with atogepant 60 mg daily for migraine treatment. Participants had chronic or episodic migraine and had previously failed several medications. Obesity increases migraine risk, highlighting the need for effective treatments. Atogepant acts on calcitonin gene-related peptide, which is linked to migraine and obesity. Weight loss was assessed during a long-term 156-week extension study. In this analysis, 595 participants were treated with atogepant after initial trials. At week 52, mean body weight decreased by 2.16 kg. About 45% of participants experienced at least 5% weight loss at any time. Approximately 30% achieved this weight loss threshold by week 52. Weight loss started as early as week 4 and plateaued around weeks 28 to 36. Higher initial body mass index correlated with greater weight loss success. No significant differences were found based on sex or race, indicating broad applicability of results. Clinical relevance: This research suggests atogepant may aid weight loss in migraine patients, potentially enhancing treatment outcomes for those with obesity.
Key Learning Points
- Atogepant 60 mg daily may help patients with migraines lose weight, which is important since obesity can worsen migraine conditions.
- In a study, participants lost an average of 2.16 kg after one year of treatment with atogepant.
- Around 45% of participants achieved at least 5% weight loss during the study, indicating significant potential for weight management.
- Weight loss benefits from atogepant began as early as four weeks into treatment and plateaued between 28 to 36 weeks.
- The effectiveness of atogepant for weight loss did not vary by sex or race, making it a broadly applicable treatment option.
Related migraine research topics
Original research
Read the original publication and review its full methods and findings on PubMed.
MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.